The Case for Intermittent Carbapenem Dosing in Stable Haemodialysis Patients.

Vanda Wen-Teng HoFelecia TayJia En WuLionel LumPaul Tambyah

Published in: Antibiotics (Basel, Switzerland) (2020)

We recommend further rigorous randomised controlled trials to investigate the clinical utility of intermittent meropenem dosing in patients on stable haemodialysis.

Keyphrases

end stage renal disease
chronic kidney disease
peritoneal dialysis
newly diagnosed
high intensity
escherichia coli
patient reported outcomes
cystic fibrosis
klebsiella pneumoniae